Cytokinetics Inc
aficamten
obstructive hypertrophic cardiomyopathy
Countdown
177days
Approval decision · ~ Dec 31, 2026 estimated
What's at stake
A final FDA approval decision on aficamten for obstructive hypertrophic cardiomyopathy is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 14h ago
“Receive potential FDA approval of the sNDA for MAPLE-HCM in Q4 2026.”